PRINCIPAL FINANCIAL GROUP INC
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1126328
DES MOINES, IA
Position in SYRE
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$5,304,338
+$5,087,497 QoQ
Shares Held
59,747
+1289.8% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#94
of 266 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRINCIPAL FINANCIAL GROUP INC holds $1,857,842,341 across 105 Biotechnology names. SYRE ranks #45 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
873,502 | $232,980,453 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
389,511 | $193,481,798 | |
| 3 | CYTK |
Cytokinetics Inc
|
1,311,664 | $111,740,655 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
1,752,753 | $94,070,253 | |
| 5 | INSM |
INSMED Inc
|
856,126 | $91,280,154 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
332,642 | $81,420,782 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
1,024,423 | $76,299,024 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
121,053 | $75,481,386 |
All Filings in SYRE
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,304,338 | 59,747 | Shares | Defined | 2026-08-04 | |
| 2026-03-31 | $216,841 | 4,299 | Shares | Defined | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||